{"text":"For the purposes of this chapter, the term:","historical":"Legislative History of Laws\n\nFor Law 16-37, see notes following ยง 28-4551.\n\nDC CODE ยง 28-4552\n\nCurrent through December 11, 2012","credits":"(Dec. 10, 2005, D.C. Law 16-37, ยง 2, 52 DCR 9061.)\n\nGENERAL NOTES\n\nThis chapter has been held unconstitutional in the case of Pharmaceutical Research and Mfrs. of America v. District of Columbia, 2005, 406 F.Supp.2d 56, 78 U.S.P.Q.2d 1822, affirmed 496 F.3d 1362, 83 U.S.P.Q.2d 1639, rehearing and rehearing en banc denied 505 F.3d 1343, 85 U.S.P.Q.2d 1144.","sections":[{"prefix":"1","text":" \"Affected party\" means any person directly or indirectly affected by excessive prices of patented prescription drugs, including any organization representing such persons or any person or organization representing the public interest."},{"prefix":"2","text":" \"High income country\" means the United Kingdom, Germany, Canada, or Australia."}],"division":{"identifier":"V","text":"Local Business Affairs"},"title":{"identifier":"28","text":"Commercial Instruments and Transactions. (Refs & Annos)"},"subtitle":{"prefix":"II","text":" Other Commercial Transactions."},"chapter":{"identifier":"45B","text":"Excessive Pricing."},"heading":{"title":"28","chaptersection":"4552","identifier":"28-4552","catch_text":"Definitions."}}